Pharmaceutical Technology19h
Editas and Genevant team up to develop gene editing therapies
Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...
Editas Medicine, Genevant Sciences enter collaboration and license agreement
Editas Medicine (EDIT) and Genevant Sciences announced that they have entered into a collaboration and nonexclusive license agreement to ...
Editas Medicine, Inc.: Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sci ...
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a ...